RxDoctor Payments Data

Tracy Ravin, MD

Ophthalmology · Melbourne, FLNPI 1801846027

Payments from drug & device makers

$3,017in general payments, 2019–2025

Across 121 payments — averaging $24.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$781
  • NEW World Medical,inc.$670
  • Alcon$397
  • Aerie Pharmaceuticals, Inc.$253
  • Rxsight Inc$247
  • Glaukos Corporation$122
  • plus $547 from 12 others

What the payments were for

  • Food & beverage$2,93897%
  • Education$803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,017 in reported general payments places this provider in the 55th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$340,899
Medicare patients
814
Services billed
2,868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine43$48,788
VyzultaLatanoprostene Bunod93$40,734
RhopressaNetarsudil Mesylate80$38,612
RocklatanNetarsudil Mesylat/Latanoprost47$32,821
CombiganBrimonidine Tartrate/Timolol66$20,293
Latanoprost1,058$15,642
LumiganBimatoprost25$15,558
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol79$14,035
Brimonidine Tartrate271$12,962
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat374$9,653
IlevroNepafenac21$9,392
SimbrinzaBrinzolamide/Brimonidine Tart33$9,146
Travoprost34$6,616
Dorzolamide-TimololDorzolamide/Timolol/Pf44$6,140
Timolol Maleate456$5,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan, Alphagan P$781$89,407147 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$253$71,433127 claims
Bausch & Lomb Americas Inc.Vyzulta$58$40,73493 claims
NovartisIlevro$80$9,39221 claims
AlconSimbrinza$397$9,14633 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$21$1,71915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →